A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with primary progressive multiple sclerosis

Trial Profile

A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with primary progressive multiple sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms INFORMS
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2018 Results of analysis assessing association between lymphocyte count and infection rates presented at the 70th Annual Meeting of the American Academy of Neurology
    • 28 Oct 2017 Results of pooled data from four trial ( INFORMS, ASCEND, ORATORIO and EXPAND), were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 21 Apr 2016 Results (n=823) assessing long-term effect of fingolimod on peripheral lymphocyte counts were presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top